

AHL/AO/2026/1099

Date: 10.02.2026

To
The BSE Limited
Listing Department
25th Floor, Phiroze Jeejeebhoy Tower
Dalal Street,
Mumbai – 400 001

Sub: Outcome of Press Release/ Media Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code: 543943

Dear Sir / Ma'am,

With reference to the captioned subject, please find enclosed a Press Release titled **“Extract of Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025”**, issued by the Company today for your information and dissemination.

The aforesaid Press Release has been **published in the following newspapers on 10 February 2026** for dissemination to investors and the general public:


- **The Times of India**
- **Dainik Jagran** (Jagran Prakashan Limited)

We request you to kindly take the above information on record and acknowledge the same.

Thanking you,

Yours faithfully,

For Asarfi Hospital Limited


Sudipa Singh



Company Secretary & Compliance Officer

Membership No.: **ACS 56989**

Encl.: Press Release

Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || www.asarfihospital.com
Phone: 7808368888, 9234302735 || Email: info@asarfihospital.com




Asarfi Hospital Ltd

CIN: L85110JH2005PLC011673

Regd. Office: 4th Floor, Asarfi Hospital, Baramuri, Bishunpur, Polytechnic, Dhanbad, Jharkhand – 828130, India

Phone: 9608833708 | E-Mail: cs@asarfihospital.com | Website: www.asarfi.in

Leading Dhanbad-based healthcare provider with a 20-year operating track record, running two hospitals across super-specialty and oncology care, delivering integrated healthcare services under one roof, spanning critical care, emergency care, cardiac care, oncology, diagnostics, and other multi-specialty services.



- **Strong growth with margin expansion:** Q3'FY26 revenue rose 40% YoY to ₹46 Cr, with EBITDA margin at 22% and PAT margin at 12%, driven by higher patient volumes, improved ARPOB and improved case mix.
- **Operational momentum across units:** IPD revenue grew 42% YoY and OPD revenue 37% YoY, supported by rising patient volumes and higher realizations; ARPOB increased to ₹24,293 (Super-Specialty) and ₹43,240 (Cancer).
- **Specialty-led performance:** Growth driven by high-acuity segments including Cardiology and Neurosciences in the Super-Specialty unit and Head & Neck and Haemato Oncology in the Cancer unit, improving overall revenue mix and complexity of care.

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(₹ in Lakhs)

Sl. No	Particulars	STANDALONE				CONSOLIDATED			
		Quarter Ended		Nine Months Ended		Quarter Ended		Nine Months Ended	
		31.12.2025	31.12.2024	31.12.2025	31.12.2024	31.12.2025	31.12.2024	31.12.2025	31.12.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from operations	4,605.87	3,289.01	12,656.94	8,667.37	4,609.52	3,289.01	12,666.09	8,667.37
2	Other Income	149.82	89.47	371.20	270.02	147.72	89.47	365.26	270.02
3	Total Income	4,755.69	3,378.48	13,028.14	8,937.39	4,757.24	3,378.48	13,031.95	8,937.39
4	Profit before Taxes	750.54	365.89	1,753.53	917.94	744.67	362.44	1,729.45	901.58
5	Profit after Taxes	548.29	271.93	1,298.34	715.10	542.42	268.48	1,274.26	698.74
6	Paid-up Equity Share Capital	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73
7	EPS (of Rs 10/- each)								
	- Basic (in Rs)	2.79	1.38	6.60	3.63	2.76	1.36	6.48	3.55
	- Diluted (in Rs)	2.79	1.38	6.60	3.63	2.76	1.36	6.48	3.55

Notes:

1. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 09, 2026.

2. The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the websites of Bombay Stock Exchange (www.bseindia.com) and Company's website at www.asarfi.in.

For and on behalf of Board of Director
Asarfi Hospital Limited
Sd/-
Udai Pratap Singh
Managing Director
DIN: 08453794

Place: Dhanbad
Date: February 09, 2026



फ

“

10 प

फ

10 प्रदेश

र



montage